Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical firm that specialises in inflammation and immunology (I&I) biological products, on Monday announced successful in-vivo preclinical study results for its anti-IL-17A/F VHH antibody fragment ('NanoAb') in a psoriatic human skin model.

The study, led by Prof. Amos Gilhar at the Technion, demonstrated significant anti-inflammatory effects comparable to standard treatments.

NanoAb aims to address mild to moderate plaque psoriasis with a local, intralesional delivery method, minimizing side effects associated with current treatments. Scinai plans to advance to a first-in-human clinical trial by late 2025, following further preclinical studies and optimisation.

Scinai Immunotherapeutics combines drug development with CDMO services, offering comprehensive support to biotech drug programs.